somatropin + somatropin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Foetal Growth Problem

Conditions

Foetal Growth Problem, Small for Gestational Age

Trial Timeline

Oct 1, 1990 → May 1, 2005

NCT ID

NCT01697644

About somatropin + somatropin

somatropin + somatropin is a approved stage product being developed by Novo Nordisk for Foetal Growth Problem. The current trial status is completed. This product is registered under clinical trial identifier NCT01697644. Target conditions include Foetal Growth Problem, Small for Gestational Age.

What happened to similar drugs?

2 of 6 similar drugs in Foetal Growth Problem were approved

Approved (2) Terminated (0) Active (4)

✅somatropin + somatropin + somatropinNovo NordiskApproved

✅somatropinNovo NordiskApproved

🔄somatropinNovo NordiskPhase 3

🔄somatropin + somatropinNovo NordiskPhase 3

🔄somatropinNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01512095	Phase 1	Withdrawn	Aug 1, 2013	Nov 1, 2013	Growth Disorder
NCT01401244	Phase 1	Completed	Jul 14, 2011	Sep 27, 2011	Genetic Disorder
NCT01529944	Phase 3	Completed	Sep 1, 2008	Oct 1, 2008	Genetic Disorder
NCT01578135	Pre-clinical	Completed	Mar 18, 2007	Oct 9, 2018	Growth Disorder
NCT00960128	Pre-clinical	Completed	Apr 1, 2006	Dec 31, 2016	Growth Hormone Disorder
NCT01502137	Phase 1	Completed	Jun 1, 2005	Nov 1, 2005	Chronic Kidney Disease
NCT00184717	Phase 3	Completed	Aug 18, 2004	Dec 28, 2009	Foetal Growth Problem
NCT01502124	Phase 3	Completed	May 8, 2001	Mar 5, 2003	Growth Hormone Disorder
NCT01734486	Approved	Completed	Sep 23, 1996	May 21, 2003	Genetic Disorder
NCT01697644	Approved	Completed	Oct 1, 1990	May 1, 2005	Foetal Growth Problem
NCT01529840	Phase 3	Completed	Jun 1, 1990	Sep 1, 2005	Genetic Disorder
NCT01518036	Phase 3	Completed	Sep 14, 1987	Apr 11, 2004	Genetic Disorder

Competing Products

8 competing products in Foetal Growth Problem

See all competitors

Product	Company	Stage	Hype Score
somatropin + somatropin + somatropin	Novo Nordisk	Approved	43
somatropin	Novo Nordisk	Phase 3	40
somatropin	Novo Nordisk	Phase 3	40
somatropin	Novo Nordisk	Pre-clinical	26
somatropin + somatropin	Novo Nordisk	Phase 3	40
somatropin	Novo Nordisk	Approved	43
somatropin	Novo Nordisk	Phase 3	40
somatropin + No treatment given + No treatment given	Novo Nordisk	Pre-clinical	26